Meeting
2022 ASCO Annual Meeting
Real-world (rw) analysis of quantitative MET copy number (CN) as a biomarker in NSCLC.
Authors
David Chun Cheong Tsui
University of Colorado Cancer Center, Aurora, CO
David Chun Cheong Tsui , Jessica Kim Lee , Garrett M. Frampton , Khaled Tolba , Geoffrey R. Oxnard , D. Ross Camidge , Alexa Betzig Schrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9123)
DOI
10.1200/JCO.2022.40.16_suppl.9123
Abstract #
9123
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
First Author: Makenzi Colleen Evangelist
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2023 ASCO Annual Meeting
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.
First Author: Jeffrey A. Scott